Phillips-Medisize Expands
Phillips-Medisize announces the expansion to its Kontiolahti, Finland site.
Phillips-Medisize, an outsource provider of design and manufacturing services for medical devices and drug delivery markets, reports the start of production and completion of the 60,000-ft2expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices, and syringes.
The expansion includes 12,900 ft2 of Class 8 clean-room manufacturing and assembly and has space for the additional expansion for molding machines and assembly. New high-speed automation lines enable the ramp up of multi-component, complex drug-delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include, multiple high-speed, fully automated assembly lines, fully automated printing lines, and several semi-automated lines.
Source: Phillips-Medisize
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
